Immunocore Holdings PLC Sponsored ADR $IMCR Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 16.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 164,000 shares of the company’s stock after purchasing an additional 23,100 shares during the period. Renaissance Technologies LLC owned 0.32% of Immunocore worth $4,945,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new stake in Immunocore in the fourth quarter valued at approximately $1,458,000. Eschler Asset Management LLP boosted its holdings in shares of Immunocore by 100.0% in the fourth quarter. Eschler Asset Management LLP now owns 80,000 shares of the company’s stock valued at $2,777,000 after acquiring an additional 40,000 shares during the period. Rhenman & Partners Asset Management AB grew its position in shares of Immunocore by 442.0% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 153,278 shares of the company’s stock worth $5,320,000 after acquiring an additional 125,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Immunocore by 287.2% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 31,674 shares of the company’s stock worth $955,000 after acquiring an additional 23,494 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Immunocore by 18.7% in the 4th quarter. Legal & General Group Plc now owns 149,333 shares of the company’s stock valued at $5,183,000 after acquiring an additional 23,577 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IMCR shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Mizuho raised their price target on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.29.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $34.50 on Friday. The stock has a fifty day moving average price of $31.54 and a 200 day moving average price of $31.33. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $27.56 and a 1-year high of $40.71. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. The company has a market cap of $1.76 billion, a PE ratio of -62.73 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $115.93 million during the quarter, compared to analyst estimates of $148.44 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.08 EPS for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.